MARKET WIRE NEWS

Subscribe to Our Newsletter

Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting

MWN-AI** Summary

Septerna, Inc. has selected SEP-204 as its first potential development candidate targeting Graves' disease and thyroid eye disease (TED). The announcement coincided with the 2026 American Thyroid Association Annual Meeting, where the company presented promising preclinical data. SEP-204 is an oral small molecule that acts as a negative allosteric modulator of the thyroid-stimulating hormone receptor (TSHR), showing a strong inhibition of TSHR activation in various animal models of Graves’ disease.

In these studies, SEP-204 demonstrated not only effective TSHR inhibition but also positive pharmacokinetic properties that indicate potential for once-daily oral dosing in humans. Key results included normalization of thyroid hormone levels, reduction of thyroid size, and improvements in ocular symptoms in animal models. Importantly, it showed favorable selectivity over closely related hormone receptors.

The company, which aims to innovate GPCR therapies for significant unmet medical needs, is preparing to move SEP-204 into Phase 1 clinical trials, slated to commence in the first quarter of 2027. Septerna’s chief medical officer, Rajiv Patni, emphasized the potential of SEP-204 to transform treatment for Graves' disease and TED, both autoimmune disorders that severely impact patient well-being.

Current therapies often fail to address the underlying causes of these conditions. SEP-204's mechanism aims to mitigate the overactivation of TSHR caused by autoantibodies, targeting the root of these disorders. With its robust preclinical data and strategic clinical plans, Septerna is positioning SEP-204 as a potential breakthrough in the treatment landscape of Graves’ disease and TED.

As Septerna advances through clinical development, updates on further findings and trial results will provide critical insights into the efficacy and safety profiles of this innovative therapy.

MWN-AI** Analysis

Septerna, Inc. (NASDAQ: SEPN) recently announced significant progress in its drug development pipeline, with the selection of SEP-204 as a leading candidate for treating Graves' disease and Thyroid Eye Disease (TED). This investigational compound, a selective TSHR negative allosteric modulator, has shown promising preclinical results, demonstrating potent inhibition of TSHR activation in relevant animal models. Given the pressing need for effective treatments targeting these conditions, this news highlights an exciting investment opportunity.

Investors may find promise in SEP-204's potential to alter treatment paradigms, as it aims to address the underlying autoimmune causes of both conditions. Current therapies often just alleviate symptoms, positioning SEP-204 as a first-in-class option that could fundamentally improve patient outcomes.

The anticipated Phase 1 clinical trial initiation in Q1 2027 underscores the company’s strategic focus on timeline-driven development. The favorable pharmacokinetic (PK) profile, which supports once-daily oral dosing, is a significant advantage. This could enhance patient compliance and acceptance, potentially leading to greater market uptake if successful.

However, potential investors must remain cognizant of the inherent risks associated with biotech investments, especially during clinical trial phases. The success of SEP-204 hinges on its continued advancement through clinical trials. Market expectations will be swayed by regular updates from Septerna regarding trial progress, and any unforeseen complications or safety concerns could significantly impact stock performance.

As Septerna establishes itself within the GPCR drug development landscape, astute investors should monitor both clinical developments and market responses to these results. Investing in Septerna may present an opportunity to capitalize on innovative healthcare solutions but requires careful consideration of the dynamic nature of the biotechnology sector.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: GlobeNewswire

Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpoints

Favorable PK profile anticipated to support once-daily oral dosing in humans

Phase 1 clinical trial initiation planned for the first quarter of 2027

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the selection of SEP-204 as its potential first-in-class development candidate for the treatment of Graves’ disease and thyroid eye disease (TED) and reported initial preclinical data ahead of a poster presentation at the 2026 American Thyroid Association (ATA) Annual Meeting on November 5.

SEP-204 is a potent and selective oral small molecule thyroid-stimulating hormone receptor (TSHR) negative allosteric modulator (NAM). SEP-204 inhibited TSHR activation in Graves’ disease animal models and has pharmacokinetic properties to support once daily dosing. A Phase 1 trial in healthy volunteers is anticipated to initiate in the first quarter of 2027.

“Based on the pre-clinical data we have generated to date, we believe SEP-204 has the potential to change the treatment paradigm for Graves’ disease and TED, two serious autoimmune endocrine diseases that can profoundly affect patients’ health and quality of life,” said Rajiv Patni, chief medical officer of Septerna. “We look forward to working closely with disease experts and the patient community to advance SEP-204 into clinical development and build upon these promising preclinical findings with clinical results.”

Preclinical studies of SEP-204 demonstrated the following key findings:

  • Potent TSHR inhibition with desirable drug-like properties and a high level of selectivity over the closely related follicle-stimulating hormone receptor (FSHR) and luteinizing hormone receptor (LHR).
  • Inhibition of thyroid-stimulating antibody (TSAb) activation of TSHR in human thyrocyte cell assays.
  • In Graves’ disease animal models, findings included restoration of normal thyroid hormone T4 levels and reductions in thyroid enlargement and orbital proptosis.
  • Dose-dependent increases in TSH levels followed by decreases in thyroid hormone levels were observed across preclinical species.
  • Generally well tolerated in 28-day GLP toxicology studies in rats and dogs.
  • High oral bioavailability and low clearance across preclinical species, with a projected human half-life of approximately 20-40 hours, which is anticipated to support once-daily oral dosing in humans.

About SEP-204, Graves’ Disease and Thyroid Eye Disease

SEP-204 is an investigational oral small molecule thyroid-stimulating hormone receptor (TSHR) negative allosteric modulator (NAM) being developed as a potential disease-modifying treatment for Graves’ disease and thyroid eye disease (TED). It is designed to block the overactivation of TSHR caused by patients’ autoantibodies in thyroid cells and orbital fibroblasts and has the potential to address both conditions. Graves’ disease is an autoimmune condition in which antibodies activate TSHR, stimulating excess thyroid hormone production and causing hyperthyroidism. Some patients also develop TED, a serious, potentially vision-threatening autoimmune condition affecting tissues behind the eyes that can cause eye bulging, swelling, pain and blurred or double vision. Current standard-of-care treatments do not address the shared underlying cause of both Graves’ disease and TED.

About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Septerna’s beliefs and expectations regarding: the potential translation of preclinical findings to clinical outcomes in patients; the potential of SEP-204 to be a first-in-class, disease-modifying treatment for Graves’ disease and TED; advancing SEP-204 into a Phase 1 clinical study and the timing thereof; SEP-204’s potential for once daily dosing; the potential of its proprietary Native Complex Platform®; and the scope of protection it is able to establish and maintain for intellectual property rights covering its Native Complex Platform® and its product candidates; among others. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: SEP-204 successfully entering and advancing through clinical trials including uncertainties related to opening investigational new drug applications and obtaining other regulatory approvals; risks related to clinical development outcomes including unexpected safety or efficacy findings; the results of preclinical studies not being predictive of future clinical outcomes; risks related to the timing of initiating clinical studies; and the scope of protection Septerna is able to establish and maintain for intellectual property rights covering its Native Complex Platform® and its product candidates; among others. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Septerna’s Quarterly Report on Form 10-Q for the three months ended June 30, 2026, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Septerna’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Septerna explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com

Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com


FAQ**

What are the expected clinical trial outcomes for Septerna Inc. SEPN's SEP-204 in treating Graves’ disease and thyroid eye disease, and how might these impact the company's market positioning?
Expected positive clinical trial outcomes for Septerna Inc.'s SEP-204 in treating Graves’ disease and thyroid eye disease could enhance its market positioning by potentially establishing the company as a key player in these therapeutic areas, attracting partnerships and investments.
How does SEP-204's pharmacokinetic profile support once-daily oral dosing in patients, positioning Septerna Inc. SEPN favorably against current treatment options?
SEP-204's favorable pharmacokinetic profile, characterized by optimal absorption and a prolonged half-life, supports once-daily oral dosing, offering a more convenient treatment alternative for patients compared to existing therapies in the market.
Can you elaborate on the preclinical efficacy of SEP-204 demonstrated in Graves’ disease animal models and its implications for Septerna Inc. SEPN's development strategy?
SEP-204 has shown promising preclinical efficacy in Graves’ disease animal models by significantly reducing hyperthyroid symptoms, which supports Septerna Inc.'s development strategy to target autoimmune thyroid disorders and advance towards clinical trials.
What are the potential risks associated with SEP-204’s clinical development, and how is Septerna Inc. SEPN preparing to mitigate these challenges as they progress through trials?
The potential risks associated with SEP-204's clinical development include safety concerns, efficacy issues, and regulatory hurdles, which Septerna Inc. is mitigating by conducting thorough preclinical studies, implementing robust clinical trial designs, and engaging with regulatory agencies early on.

**MWN-AI FAQ is based on asking OpenAI questions about Septerna Inc. (NASDAQ: SEPN).

Septerna Inc.

NASDAQ: SEPN

SEPN Trading

-4.3% G/L:

$49.20 Last:

941,158 Volume:

$51.90 Open:

iqst Ad 300

SEPN Latest News

$1,195,470,926
19,969,290
0.21%
25
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco

Check Your Online Brokerage For SEPN

Link Market Wire News to Your X Account

Download The Market Wire News App

Schedule a 30 minute Brand Awareness meeting with Market Wire News